Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsIn March 2018, BAT4306F, the recombinant glycosylation-modified anti-human-CD20 monoclonal antibody solution for injection, approved for phase I clinical trials in China. BAT4306Fis a next generation anti-CD20 monoclonal antibody. The CD20 receptor is a validated drug target with monoclonal antibodi...
GUANGZHOU, CHINA, March 29, 2018 – Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2018 American Association for Cancer Research ("AACR") Annual ...
GUANGZHOU, CHINA, January 5, 2018 – Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies as well as a pipeline of biosimilars, today announced that Bert Thomas, PhD, MBA, Bio-Thera’s Senior Vice President of Business Development, ...